The analysis of ROC curve demonstrated that TAFI shows a better discriminatory ability for mild and complicated forms of AP than inflammatory biomarkers (fibronectin and CRP), with a sensitivity of 83.30% and a specificity of 56.00%.
TAFI is one of the coagulation parameters that following the start of the inflammatory process can influence the severity and outcome of AP.
Existing clinical studies have investigated the value and effect of TAFI in patients with ulcerative colitis and Crohn's disease, type 2 diabetes, rheumatoid arthritis, and cardiovascular diseases; studies regarding the role of TAFI in AP are limited to date (9,27-29).
In conclusion, we found that plasma TAFI levels are higher in patients with complicated forms of AP.
(10.)Leung LL, Nishimura T, Myles T Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI) Adv Exp Med Biol 2008, 632 61-9.
(24.)Bouma BN, Meyers JC Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) J Thromb Haemost 2003, 1 1566-74.
(25.)Boffa MB, Nesheim ME, Koschinsky ML Thrombin activable fibrinolysis inhibitor (TAFI) molecular genetics of an emerging potential risk factor for thrombotic disorders Curr Drug Targets Cardiovasc Haematol Disord 2001, 1 59-74.